Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.48 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15556459 | 1.00 | CHRNA7 (0.48) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL493319 | 0.88 | CHRNA7 (0.50) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL15556611 | 0.86 | HTR3A (0.51) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL491959 | 0.86 | HTR3A (0.51) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL492429 | 0.85 | CHRNA7 (0.44) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL492961 | 0.85 | CHRNA7 (0.50) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL492524 | 0.84 | CHRNA7 (0.52) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL493149 | 0.82 | CHRNA7 (0.48) | CHRNA7HTR3A | |
| SCHEMBL4617352 | 0.82 | CHRNA7 (0.45) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL492138 | 0.82 | CHRNA7 (0.45) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106066-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885HTR3A 438/4885HTR3E 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.